Date
Addressing a Trifecta of Overlooked IV Medication Risks
A Midday Symposium conducted at the 49th ASHP Midyear Clinical Meeting and Exhibition
Monday, December 8, 2014 - 11:30am-1:00pm PST
Hilton Anaheim, Pacific Ballroom D
Click here to register to attend in Anaheim
Click here to register to attend via Webinar
- Equipment Requirements
- * Computer with broadband Internet access
- * Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
- Click here for detailed software requirements.
Overview
The causes of IV medication preparation and administration errors are many, but during the past year the Institute for Safe Medication Practices (ISMP) and other healthcare organizations have identified three specific categories of risk that have been unnoticed and inadequately addressed by most healthcare organizations. This symposium is designed to help participants address: failure to factor in IV container overfill when preparing certain IV drug infusions; unnecessary dilution of IV medications at the bedside; and unsafe use of syringes, needles, and vials. Expert speakers will discuss these risky practices, clarify misperceptions regarding regulatory requirements, and provide participants with practical recommendations to prevent errors.
Objectives
The target audience for this activity includes pharmacists in health-system settings. At the completion of this symposium, the participant should be able to:
- Identify conditions that require pharmacists to factor in IV container overfill when preparing IV admixtures.
- Describe a standard process that can be implemented for IV admixture that factors in IV container overfill and produces a label that guides nurses to deliver the correct volume associated with the prescribed dose.
- List three reasons that nurses might dilute adult IV medications unnecessarily before administration.
- Describe strategies to increase awareness of the risks associated with diluting adult IV medications and reduce its occurrence.
- Discuss regulatory and accreditation requirements that promote safe use of vials.
- List three ways that pharmacists can guide nurses to follow safe injection practices.
Agenda
10:45am - Doors Open
11:30am-1:00pm - Symposium
Space is limited and pre-registration is encouraged. Pre-registration is for planning purposes only and seating will be available on a first-come, first-served basis.
Food and beverage are no longer provided at Midday Symposia. This ASHP policy considers the varied internal policies of commercial supporters related to the Physician Payments Sunshine Act. You are welcome to bring your lunch to the session.
Topics and Faculty
Introduction and Overview
Michael R. Cohen, RPh, MS, ScD, FASHP, President, ISMP
Understanding and Managing IV Container Overfill
Michael R. Cohen, RPh, MS, ScD, FASHP, President, ISMP
Unsafe Intravenous Medication Dilution at the Bedside
Judy L. Smetzer, RN, BSN, FISMP, Vice President, ISMP
Regulatory and Accreditation Requirements for Syringes, Needles, and Vials
Darryl S. Rich, PharmD, MBA, FASHP, Medication Safety Specialist, ISMP
CE Accreditation
Pharmacists
This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-14-228-L05-P has been assigned to this knowledge-based live CE activity (initial release date December 8, 2014). This CE activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Successful completion of the online post-test and evaluation at www.ProCE.com no later than January 9, 2015 is required to receive CE credit. CE credit will be automatically uploaded to NABP/CPE Monitor within 1 to 2 weeks of the completion of the post-test and evaluation. No partial credit will be given.
Disclosure
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Cohen has no relevant commercial or financial relationships to disclose. Dr. Rich has no relevant commercial or financial relationships to disclose. Ms. Smetzer has no relevant commercial or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
Funding
This symposium is funded through an educational grant from Hospira.